MicroConstants China Receives Endorsement of OECD GLP Compliance

BEIJING, May 26, 2011 -

MicroConstants China Inc., a Contract Research Organization (CRO)
conducting preclinical pharmacokinetics studies and providing full-service
early stage clinical trial management in Beijing, announces the Endorsement
of Compliance with the OECD Principles of Good Laboratory Practice (GLP) in
the areas of analytical chemistry and pharmacokinetic studies from the
Netherlands GLP Compliance Monitoring Programme. MicroConstants China is the
first test facility in China to receive an Endorsement of GLP Compliance from
the Netherlands inspectorate.

Dr. Q. David Yang, chief executive officer of MicroConstants China, is
thrilled with the OECD Endorsement of GLP Compliance. "The Endorsement
illustrates our commitment to quality and validates our bioanalytical
laboratory's capability of carrying out method validation and bioanalysis
under OECD Principles of GLP."

MicroConstants China received the Endorsement on May 23, 2011 following a
one week assessment and onsite inspection conducted by the Netherlands GLP
Compliance Monitoring Programme in early 2011. Late last year, they also
received ISO-17025 accreditation from the China National Accreditation
Service for Conformity Assessment (CNAS). These accomplishments can be
attributed to MicroConstants San Diego's quality systems, which
MicroConstants China adopted and successfully implemented at the Beijing
laboratory in 2009.

"This Endorsement, along with the CNAS accreditation achieved last year,
demonstrates that our Beijing team is capable of conducting high quality
contract research services equivalent to those provided by our San Diego
bioanalytical laboratory," said Dr. Gilbert Lam, co-founder of MicroConstants
China and president of MicroConstants, Inc. in San Diego, California. "This
is a significant accomplishment and we are very proud of their progress."

About MicroConstants China Inc.

MicroConstants China Inc. is a Contract Research Organization (CRO) that
was established in 2007 by the founder and president of MicroConstants, Inc.,
a bioanalytical and PK specialty CRO in San Diego, California with over a
decade of GLP compliance history. Located in Beijing, MicroConstants China
provides preclinical and clinical pharmacokinetic analysis and early stage
clinical trial management services, including clinical site qualification,
trial monitoring, data management, biostatistics, and clinical summary
reports to pharmaceutical and biotech companies worldwide. Additionally, the
CRO offers QA audit and drug development project management services for
preclinical toxicology and pharmacology studies in China. Its bioanalytical
laboratory is fully GLP-compliant with USFDA, OECD, Japan MHLW and China SFDA
guidelines. For more information about MicroConstants China and the contract
research services they provide, please visit
www.microconstants.com/china.

Heather McMahon of MicroConstants, Inc., +1-866-232-9497, hmcmahon at microconstants.com